Table 1.
Patient characteristics (LAD, left atrial diameter; AF, atrial fibrillation; LVEF, left ventricular ejection fraction; DOAC, direct oral anticoagulation). * Left atrial fibrosis was measured using the area measurement tool based on bipolar low-voltage.
| Parameter | Patients; n = 50 |
|---|---|
| Age (y) | 67 ± 11 |
| Male sex (%) | 25 (50%) |
| BMI (kg/m2) | 29.5 ± 5.4 |
| LAD (mm) | 46 ± 7 |
| AF-Duration (months) | 30 ± 25 |
| CHA2DS2-VASc-Score | 2.9 ± 1.6 |
| Hypertension (%) | 37 (74%) |
| Diabetes (%) | 7 (14%) |
| Prior stroke (%) | 10 (20%) |
| Heart failure (%) | 20 (40%) |
| LVEF (%) | 52 ± 5 |
| Drug therapy | |
| Antiarrhythmic drugs | 10 (20%) |
| Beta-blocker | 39 (78%) |
| ACE-Inhibitor | 39 (78%) |
| Statin | 22 (44%) |
| Anticoagulation | 50 (100%) |
| Phenprocoumon | 5 (10%) |
| DOAC | 45 (90%) |
| Amount of fibrosis * | |
| 0–10% | 2 (4%) |
| 10–20% | 2 (4%) |
| 20–30% | 17 (34%) |
| > 30% | 29 (58%) |